{"resourceType":"ResearchStudy","phase":{"coding":[{"code":"phase-III","display":"Therapeutic confirmatory  (Phase III)","system":"https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-study-phase-source-code-system","version":"0.3.0"}]},"identifier":[{"assigner":{"display":"Reference to primary assigner","reference":"Organization/ctis","type":"Organization"},"use":"official","value":"2022-500014-26-00"}],"extension":[{"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-review-date","valueInstant":"2023-04-12T00:00:00.000Z"},{"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-therapeutic-area","valueString":"[Traduction locale] Diseases [C] - Neoplasms [C04]"},{"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-recruitment-period","valuePeriod":{"start":"2022-06-30T00:00:00.000Z"}},{"extension":[{"url":"name","valueString":"F. Hoffmann-La Roche AG"},{"url":"role","valueCodeableConcept":{"coding":[{"code":"lead-sponsor","display":"lead-sponsor","system":"https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-study-party-role-code-system","version":"0.3.0"}]}},{"url":"party","valueReference":{"display":"Reference to primary sponsor","reference":"Organization/2022-500014-26-00-primary-sponsor","type":"Organization"}}],"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition-eclaire-associated-party-r5.html"}],"title":"[Traduction locale] A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER","enrollment":[{"display":"Reference to group detailing study characteristics","reference":"Group/2022-500014-26-00-enrollment-group","type":"Group"}],"condition":[{"id":"disease-condition-2022-500014-26-00","text":"[Traduction locale] Locally-Advanced or Metastatic breast cancer (MBC)"},{"id":"meddra-condition-2022-500014-26-00-10070575","coding":[{"code":"10070575","display":"Cancer du sein à récepteurs aux oestrogènes positifs","system":"http://terminology.hl7.org/CodeSystem/mdr","version":"2.0.1"}]},{"id":"meddra-condition-2022-500014-26-00-10065430","coding":[{"code":"10065430","display":"Cancer du sein HER2 positif","system":"http://terminology.hl7.org/CodeSystem/mdr","version":"2.0.1"}]}],"site":[{"display":"Reference to site","reference":"Location/2022-500014-26-00-0-site","type":"Location"}],"meta":{"lastUpdated":"2023-04-12T00:00:00.000Z","profile":["https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-researchstudy"]},"contact":[{"extension":[{"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-name","valueHumanName":{"family":"Trial Information Support Line-TISL, Switzerland","given":["Head of EU"],"use":"official"}}],"telecom":[{"system":"phone","use":"work","value":"0041616881111"},{"system":"email","use":"work","value":"global.rochegenentechtrials@roche.com"}]},{"extension":[{"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-name","valueHumanName":{"given":[],"use":"official"}},{"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-type","valueCodeableConcept":{"coding":[{"code":"PUB","display":"Publique / Public","system":"https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-type-contact-code-system","version":"0.3.0"}]}}],"telecom":[{"system":"phone","use":"work"},{"system":"email","use":"work"}]}],"location":[{"coding":[{"code":"BE","display":"Belgium","system":"urn:iso:std:iso:3166","version":"4.0.1"}]},{"coding":[{"code":"DE","display":"Germany","system":"urn:iso:std:iso:3166","version":"4.0.1"}]},{"coding":[{"code":"ES","display":"Spain","system":"urn:iso:std:iso:3166","version":"4.0.1"}]},{"coding":[{"code":"FR","display":"France","system":"urn:iso:std:iso:3166","version":"4.0.1"}]},{"coding":[{"code":"HU","display":"Hungary","system":"urn:iso:std:iso:3166","version":"4.0.1"}]},{"coding":[{"code":"IT","display":"Italy","system":"urn:iso:std:iso:3166","version":"4.0.1"}]},{"coding":[{"code":"PL","display":"Poland","system":"urn:iso:std:iso:3166","version":"4.0.1"}]},{"coding":[{"code":"PT","display":"Portugal","system":"urn:iso:std:iso:3166","version":"4.0.1"}]}],"id":"2022-500014-26-00","category":[{"coding":[{"code":"REG536","display":"REG536 (CTIS)","system":"https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-regulation-code-code-system","version":"0.3.0"}]},{"coding":[{"code":"study-ctis","display":"un essai clinique (CTIS)","system":"https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-reglementation-precision-code-system","version":"0.3.0"}]}],"status":"active"}